Global X-linked Adrenoleukodystrophy Market - Industry Trends and Forecast to 2028

Market Analysis and Insights: Global X-linked Adrenoleukodystrophy Market

Global X-linked Adrenoleukodystrophy Market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to account to grow at a CAGR of 7.10% in the above mentioned forecast period.

X-linked Adrenoleukodystrophy (X-ALD) is a rare genetic disorder. This condition is caused due to the abnormality in ABCD1 gene which is present on the X chromosome. It further results in the accumulation of very-long-chain fatty acids (VLCFAs) in the brain, nervous system, and adrenal gland. This accumulation in tissues leads to the damage of myelin which causes neurological problems in patients.

Rise in the prevalence of X-linked adrenoleukodystrophy, inevitable inheritance of the disease, advancement of therapies for treatment, and increase in the awareness towards genetic diseases coupled with genetic counselling. All these factors will increase the growth of X-linked adrenoleukodystrophy market. Growing government funds and support will also drive the market growth.

Rise in number of R&D activities and clinical trials on emerging drugs are expected to provide beneficial opportunities for the global X-linked adrenoleukodystrophy market in the forecast period of 2021-2028.

Treatment of X-linked adrenoleukodystrophy includes stem cell therapy which has serious side effects such as interstitial pneumonia, liver damage, and mucositis. Hydrocortisone is a major drug in adrenal insufficiency treatment which affects cortisol levels in the patients and also results in the weakening of the immune system. Mutation of cells can also occur due to gene therapy. These factors will hamper the global X-linked adrenoleukodystrophy market report.

High cost of treatment and focus of developing therapies on the novel approaches to treat the rare diseases are the factors that will challenge the global X-linked adrenoleukodystrophy market in the forecast period mentioned above.

This X-linked adrenoleukodystrophy market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global X-linked adrenoleukodystrophy market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

X-linked Adrenoleukodystrophy Market Scope and Market Size

The X-linked adrenoleukodystrophy market is segmented on the basis of type, symptoms, treatment, diagnosis, end-users, and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

• On the basis of type, the X-linked adrenoleukodystrophy market is segmented into adrenomyeloneuropathy (AMN), adult cerebral ALD, childhood cerebral ALD, and Addison’s-only ALD.
• On the basis of symptoms, the X-linked adrenoleukodystrophy market is segmented into paraparesis, adrenocortical insufficiency, psychiatric disorders, dementia, urinary and genital tract disorders, and others.
• On the basis of treatment, the X-linked adrenoleukodystrophy market is segmented into stem cell transplant, adrenal insufficiency treatment, gene therapy, physical therapy, corticosteroids, lorenzo’s oil, and others. Others have been further segmented into emerging drugs. Emerging drugs have been further sub divided into Lenti D and Leriglitazone.
• On the basis of diagnosis, the X-linked adrenoleukodystrophy market is segmented into blood testing, MRI, vision screening, skin biopsy, and fibroblast cell culture.
•  On the basis of end-users, the X-linked adrenoleukodystrophy market is segmented into clinics, hospitals, diagnostic centres, and others.
• The X-linked adrenoleukodystrophy market is also segmented on the basis of distribution channel into hospital pharmacy, retail pharmacy, and online pharmacy.

Global X-linked Adrenoleukodystrophy Market Country Level Analysis

Global X-linked adrenoleukodystrophy market is analyzed, and market size information is provided by the country, type, symptoms, treatment, diagnosis, end-users and distribution channel as referenced above.

The countries covered in the global X-linked adrenoleukodystrophy market report are the U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa.

North America dominates the X-linked adrenoleukodystrophy market due to the existence of major key players, high prevalence rate, increasing social awareness, well-developed healthcare sector, and increase in the government support for research & development in this region. Global X-linked adrenoleukodystrophy market in the Asia-Pacific is expected to grow during the forecast period, because of growing focus of pharmaceutical companies on advancement of therapies for treatment of rare diseases, growing government support, and rising healthcare expenditure. 

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

Global X-linked adrenoleukodystrophy market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Global X-linked Adrenoleukodystrophy Market Share Analysis

Global X-linked adrenoleukodystrophy market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to global X-linked adrenoleukodystrophy market.

The major players covered in the global X-linked adrenoleukodystrophy market report are agtc, bluebird bio, MINORYX THERAPEUTICS SL, SwanBio Therapeutics, Inc., Viking Therapeutics, Novartis AG, Sanofi, Pfizer Inc., Sumitomo Corporation, Johnson & Johnson Private Limited, AstraZeneca, Cipla Inc., Abbott, Bayer AG, Merck KGaA, and GlaxoSmithKline plc, among other domestic and global players.  Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

For instance

In January 2020, Minoryx Therapeutics received lead drug candidate’s approval, Leriglitazone (MIN-102), for treatment of all forms of x- adrenoleukodystrophy.

SKU-63683